Journal of Obesity & Metabolic Syndrome



June, 2024 | Vol.33 No.2

J Obes Metab Syndr 2023; 32(3): 247-258

Published online September 30, 2023

Copyright © Korean Society for the Study of Obesity.

Herbal Metabolites as Potential Carbonic Anhydrase Inhibitors: Promising Compounds for Cancer and Metabolic Disorders

Ebrahim Yarmohammadi1, Maryam Khanjani1, Zahra Khamverdi1, Marzieh Savari2, Amir Taherkhani2,*

1Department of Restorative Dentistry, School of Dentistry, Dental Research Center, Hamadan University of Medical Sciences, Hamadan; 2Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Correspondence to:
Amir Taherkhani
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Street, Hamadan 6517838736, Iran
Tel: +98-9183145963
Fax: +98-8138276299

Received: April 15, 2023; Reviewed : June 30, 2023; Accepted: September 13, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background: Human carbonic anhydrases (CAs) play a role in various pathological mechanisms by controlling intracellular and extracellular pH balance. Irregular expression and function of CAs have been associated with multiple human diseases, such as obesity, cancer, glaucoma, and epilepsy. In this work, we identify herbal compounds that are potential inhibitors of CA VI.
Methods: We used the AutoDock tool to evaluate binding affinity between the CA VI active site and 79 metabolites derived from flavonoids, anthraquinones, or cinnamic acids. Compounds ranked at the top were chosen for molecular dynamics (MD) simulations. Interactions between the best CA VI inhibitors and residues within the CA VI active site were examined before and after MD analysis. Additionally, the effects of the most potent CA VI inhibitor on cell viability were ascertained in vitro through the 2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.
Results: Kaempferol 3-rutinoside-4-glucoside, orientin, kaempferol 3-rutinoside-7-sophoroside, cynarin, and chlorogenic acid were estimated to establish binding with the CA VI catalytic domain at the picomolar scale. The range of root mean square deviations for CA VI complexes with kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin was 1.37 to 2.05, 1.25 to 1.85, and 1.07 to 1.54 Å, respectively. The MTT assay results demonstrated that cynarin had a substantial effect on HCT-116 cell viability.
Conclusion: This study identified several herbal compounds that could be potential drug candidates for inhibiting CA VI.

Keywords: Anthraquinones, Neoplasms, Carbonic anhydrases, Cinnamic acid, Flavonoids, Inhibitor, Obesity

Zinc-containing enzymes known as human carbonic anhydrases (CAs) facilitate a reversible reaction between carbon dioxide (CO2) and proton/bicarbonate ions.1 These enzymes govern extracellular and intracellular pH homeostasis, contributing to critical pathophysiological processes.2 The existing literature has identified 12 active human CAs with distinct tissue-specific and sub-cellular expression.3 Mounting evidence suggests a connection between irregular expression or activity of CAs and various human disorders, including cancer,4 glaucoma,5 obesity,6 and epilepsy.7 Consequently, researchers are working to develop CA inhibitors and activators with diverse potential medical applications.8 Among the CA subtypes, CA VI exists exclusively in serum,9 saliva,10 milk,11 the alimentary canal,12 and respiratory airways.13 Earlier investigations have associated CA VI dysregulation with certain cancers, such as salivary gland carcinoma,14 highlighting its potential as a cancer biomarker.15 Furthermore, studies have noted a correlation between heightened CA VI activity and dental caries.16 For example, Picco et al.17 demonstrated elevated CA VI activity in the dental biofilms of children with caries compared with caries-free children. Moreover, Al-Mahdi et al.18 established a positive link between CA VI copy numbers and increased caries on both smooth and occlusal surfaces, indicating that CA VI potentially plays a role in the progression of dental caries.

For primary care, the use of herbal remedies has become increasingly prevalent during the past decade.19,20 Flavonoids, a category of polyphenolic compounds, naturally accumulate in numerous plants and are found in fruits, beverages, and vegetables. These secondary metabolites have a range of health advantages, including antioxidative, anti-inflammatory, anticancer, and anti-tooth-caries properties.21 Cinnamic acid derivatives are a cluster of herbal compounds with a foundational C6–C3 structure. These aromatic carboxylic acids are prominently present in the cellular walls of plants and play a role in plant growth, development, and defense against diseases.22 A body of literature underscores the characterization of cinnamic acids as compounds with anticancer and anti-tooth-caries attributes.23 Anthraquinones (AQs), a substantial group of secondary metabolites, are primarily discovered in fungi, Rubiaceae, Polygonaceae, and Rhamnaceae.24 Prior investigations have linked AQs with antioxidant, anti-inflammatory, antimicrobial, anticancer, and anti-tooth-caries qualities.25,26

Within this context, we wondered about the potential CA VI inhibitory properties of flavonoids, cinnamic acid derivatives, and AQs and their implications for therapeutic interventions to treat various human disorders. Therefore, the binding affinity between selected herbal compounds and the active site of CA VI was scrutinized using AutoDock 4.0 software ( Additionally, the stability of the docked poses for the most potent flavonoid, cinnamic acid derivative, and AQ was investigated through molecular dynamics (MD) simulations. Then we explored plausible interactions between the most potent inhibitors and residues within the catalytic site of CA VI. Validation of such computational predictions commonly depends on in vitro tests with relevant cell lines. Among cancers, colorectal cancer (CRC) has the third-highest prevalence and fourth-highest mortality rate.27 In this study, we performed an in vitro investigation with the HCT-116 human CRC cell line, which was originally derived from a malignant colon tumor, to assess the cytotoxic effects of the most potent CA VI inhibitor that we identified. The 2,5-diphenyl-2H-tetrazolium bromide (MTT) method—an extensively used technique for estimating cell viability and ascertaining compound cytotoxicity—was chosen to gauge those effects.

Structure preparation

The three-dimensional coordinates of the CA VI structure were downloaded from the Protein Data Bank (PDB; at 1.3 Å X-ray resolution (PDB ID: 6QL2).14 The 6QL2 file included one polypeptide chain (chain A) with 258 residues and an ethoxzolamide inhibitor (PDB ID, EZL; PubChem ID, 3295). The inhibitor compound was removed from the CA VI structure, and energy optimization of the enzyme was performed using Discovery Studio Client version (BIOVIA). The binding affinity between 79 small molecules (45 flavonoids, 21 AQs, and 12 cinnamic acids), with EZL as a positive control inhibitor, and the CA VI active site was examined using AutoDock 4.0 software. The structures of the ligands were obtained as spatial data file (SDF) files, converted into PDB format, and then energy-minimized following procedures from our previous reports.24,28

Molecular docking

A Windows-based system with a 64-bit operating system, 32 GB random access memory (RAM), and Intel Core i7 central processing unit (CPU) (Intel) was used for molecular docking and dynamics simulations.29 The docking procedures were conducted using AutoDock 4.0 software, and the MD simulations were executed in Discovery Studio Client version The AutoDock 4.0 tool uses the Lamarckian genetic algorithm to compute the Gibbs free binding energy between ligands and receptors. Preparation of the CA VI structure involved the inclusion of polar hydrogen atoms and Kollman charges. The protein and ligand structures were readied as PDB partial charge (Q) & atom type (T) (PDBQT) files to facilitate the molecular docking processes.

The identification of central residues within the active site of CA VI was achieved by analyzing the two-dimensional structures of several inhibitors within the catalytic domain of the protein. These investigations were conducted across multiple studies led by Kazokaitė et al.14 Noteworthy among these inhibitors were V50 (PubChem ID, 71299336), found within the 6QL1 file; EZL, incorporated in the 6QL2 file; and V14 (PubChem ID, 73774785), located within the 6QL3 file. As a result of those studies, a set of 18 amino acids was recognized within the CA VI active site: Asn62 (asparagine), His64 (histidine), Thr65 (threonine), Gln67 (glutamine), Gln92, His94, His96, Glu106 (glutamic acid), His119, Val121 (valine), Tyr131 (tyrosine), Gln135, Leu198 (leucine), Thr199, Thr200, Pro202 (proline), Thr204, and Trp209 (tryptophan). Based on the coordinates of these identified residues, the specifications for the grid box were established as follows: spacing, 0.375 Å; X-dimension, 56; Y-dimension, 66; Z-dimension, 62; X-center, 15.924; Y-center, –4.825; and Z-center, 15.029.

Next, 46 flavonoids, 21 AQs, and 12 cinnamic acids, all ligands, were subjected to 50 docking runs each. Among the runs, the most negative ΔGbinding value within the largest cluster of the root mean square deviation (RMSD) table is reported as the binding affinity between the molecules. In this study, compounds exhibiting ΔGbinding values higher than –10 kcal/mol were categorized as the top-ranked CA VI inhibitors. To uncover potential interactions between these top-ranked inhibitors and the residues integrated within the active site of CA VI, we used BIOVIA Discovery Studio Visualizer version

MD computer simulations

Among the array of flavonoids, AQs, and cinnamic acids, the most potent inhibitors of CA VI were singled out for MD analyses in 40-ns computer simulations. The parameters for the MD simulations were aligned with the advanced settings outlined in our earlier report.28 From the MD analysis, we gleaned insights into the interactions between the compounds and amino acids within the CA VI active site. Throughout the simulation, both the RMSD of the backbone atoms and the root mean square fluctuation (RMSF) were scrutinized to understand their dynamics.

Ethical approval

This study was approved by the Ethics Committee/Institutional Review Board of Hamadan University of Medical Sciences, Hamadan-Iran (IRB no. IR.UMSHA.REC.1401.141). Informed consent was waived by the board.

Cell viability studies

Human HCT-116 epithelial CRC cells were procured from the Pasteur Institute of Iran Cell Bank. Subsequently, the HCT-116 cells were plated in a 96-well format at a density of 10,000 cells per well. The cells were cultivated until they reached 70% to 80% confluence. Then they were exposed to varying concentrations of the most potent CA VI inhibitor (0, 10, 20, 40, 80, 120, and 160 µM) for 24, 48, and 72 hours. The MTT reagent was added to each well during the assay and incubated with the cells at 37 °C with 5% CO2 for 4 hours. Viable cells converted the MTT into insoluble purple formazan crystals. Post-incubation, dimethyl sulfoxide was added, and a microplate reader was used to measure the absorbance at a wavelength of 570 nm to determine the percentage of viable cells. The obtained data were analyzed using both Excel (Microsoft) and GraphPad Prism 5 software (GraphPad Software Inc.).

Binding affinity assessment

The analysis conducted through AutoDock 4.0 revealed that 14 flavonoids, three AQs, and three cinnamic acid derivatives had ΔGbinding values below –10 kcal/mol. These were designated as the top-ranked herbal inhibitors of CA VI in this study. The flavonoids were kaempferol 3-rutinoside-4-glucoside, orientin, kaempferol 3-rutinoside-7-sophoroside, amentoflavone, rutin, isoquercitrin, vicenin-2, vitexin, quercitrin, astragalin, quercetin-3-rhamnoside, kaempferol 7-O-glucoside, nicotiflorin, and cynaroside. Among the AQs, aloe-emodin 8-glucoside, hypericin, and pulmatin (chrysophanol-8-O-glucoside) emerged as the top CA VI inhibitors. Cynarin, chlorogenic acid, and rosmarinic acid had the most negative ΔGbinding values among the cinnamic acid derivatives.

Remarkably, five compounds, kaempferol 3-rutinoside-4-glucoside, orientin, kaempferol 3-rutinoside-7-sophoroside, cynarin, and chlorogenic acid, were estimated to establish attachments with the CA VI catalytic domain at picomolar (pM) concentrations. They were consequently identified as the most potent CA VI inhibitors in this study; the ΔGbinding values between them and the CA VI catalytic domain were –15.60, –13.92, –12.70, –14.93, and –12.42 kcal/mol, respectively, and their calculated inhibition constant (Ki) values were 3.69, 62.48, 493.64, 11.33, and 783.13 pM. A comprehensive list of the ΔGbinding and Ki values between the studied ligands and the CA VI active site is presented in Table 1. Fig. 1 compares the ΔGbinding values between the top-ranked components and the positive control inhibitor and the CA VI catalytic domain.

Protein-ligand interactions

The interactions between the top-ranked compounds identified in this study (and the positive control inhibitor) and residues within the CA VI active site were assessed using BIOVIA Discovery Studio Visualizer. Additionally, comparisons were performed before and after 40 ns of MD simulations for three compounds: kaempferol 3-rutinoside-4'-glucoside, aloe-emodin 8-glucoside, and cynarin. Those findings are presented in Table 2 and illustrated in Fig. 2.

Among the flavonoids, orientin exhibited the highest number of hydrogen bonds with residues inside the CA VI active site. Specifically, the interactions involved Asn62, His64, Gln135, and Pro201. Among the AQs, aloe-emodin 8-glucoside established four hydrogen bonds with Glu69, Leu198, Thr199, and Thr200. Similarly, rosmarinic acid had three hydrogen bonds, forming interactions with Pro201 and Pro202.

Before the MD analysis, kaempferol 3-rutinoside-4'-glucoside, aloe-emodin 8-glucoside, and cynarin exhibited one, four, and one hydrogen bonds, respectively. Following 40 ns of MD simulation, the number of hydrogen bonds for kaempferol 3-rutinoside-4'-glucoside and cynarin increased to seven and two, respectively. Notably, the count of hydrogen bonds for aloe-emodin 8-glucoside remained unchanged after the MD simulation. Hydrogen bonds with distances exceeding 5 Å were omitted from Table 2 for clarity and relevance.

MD computer simulations

The RMSD ranges for CA VI in complex with kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin were 1.37 to 2.05, 1.25 to 1.85, and 1.07 to 1.54 Å, respectively. These compounds’ corresponding average RMSF values were 1.70, 1.57, and 1.34 Å. Notably, the enzyme complexes involving kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin appeared to attain a state of relative stability at approximately 30, 25, and 35 ns, respectively, as illustrated in Fig. 3A.

Furthermore, the mean RMSF values for the CA VI residues complexed with kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin were 1.72, 1.57, and 1.32 Å, respectively. Most notably, the residues integrated within the CA VI active site exhibited lower fluctuations than the other residues, as depicted in Fig. 3B.

The structural alignment of CA VI in complex with aloe-emodin 8-glucoside, kaempferol 3-rutinoside-4-glucoside, and cynarin, both before and after 40 ns of MD simulations, is visually presented in Fig. 4.

MTT assay

Cell viability was assessed across various concentrations of cynarin, the most potent CA VI inhibitor. The results from the MTT assays indicate that cynarin induced cytotoxic effects in HCT-116 cells, with an observed half maximal inhibitory concentration of 199.9 µg/mL, as depicted in Supplementary Fig. 1.

This study employed a comprehensive computational approach to identify potential inhibitors of CA VI from a pool of 79 plant-based compounds: 46 flavonoids, 21 AQs, and 12 cinnamic acid derivatives. In that analysis, kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin emerged as the strongest CA VI inhibitors from the categories of flavonoids, AQs, and cinnamic acid derivatives, respectively. The ΔGbinding value between kaempferol and the CA VI active site was –7.99 kcal/mol. In contrast, the binding affinities for kaempferol 7-O-glucoside, kaempferol 3-rutinoside-7-sophoroside, and kaempferol 3-rutinoside-4'-glucoside were –10.60, –12.70, and –15.60 kcal/mol, respectively. This suggests that appending a sugar moiety to kaempferol enhances its binding affinity to the CA VI catalytic domain. Notably, kaempferol 3-rutinoside-4-glucoside established one hydrogen bond and three hydrophobic interactions with residues within the CA VI active site (Trp5, His64, Tyr131, and Thr200) before the MD simulation. After 40 ns of MD computer simulation, the compound formed seven hydrogen bonds with Asn62, Gln67, Glu69, Gln92, Tyr131, and Pro201. Kaempferol is recognized as a metabolite and has demonstrated efficacy in reducing the incidence of breast30 and colon31 cancers. Its anticancer properties predominantly involve inducing apoptosis and suppressing cell proliferation in cancer cells.32 Notably, kaempferol has also been identified as an anti-tooth-caries agent. Research has indicated its antibacterial activity against leading oral pathogens that contribute to dental caries, including Porphyromonas gingivalis and Streptococcus mutans.33

Before the MD simulation, aloe-emodin 8-glucoside established four hydrogen bonds and two hydrophobic interactions with residues within the CA VI active site (Glu69, His94, Val121, Leu198, Thr199, and Thr200). After the MD analysis, the ligand exhibited four hydrogen bonds and one hydrophobic interaction with residues within the CA VI catalytic site (His94, Thr200, and Pro201). In a related study, Mohammed et al.34 conducted an integrated investigation combining in silico and in vitro analyses to explore the anticancer and antibacterial properties of metabolites extracted from the Lycium shawii shrub. They identified five metabolites in L. shawii: costunolide, catechin, lyciumaside, emodin, and aloe-emodin 11-O-rhamnoside. Notably, emodin demonstrated good binding affinity to CA IX, indicating its potential for anticancer and antibacterial activity against pathogens such as methicillin-resistant Staphylococcus aureus, S. mutans, Escherichia coli, and Klebsiella pneumoniae.

Cynarin, known chemically as 1,3-O-dicaffeoylquinic acid, is a plant-derived compound primarily sourced from artichokes.35 It has garnered attention for its range of advantageous attributes, particularly its antioxidant effects, antihypertensive properties, and ability to lower cholesterol.36 Before the MD simulation, cynarin established one hydrogen bond and one hydrophobic interaction with Leu198 and Pro201 within the CA VI active site. Following the MD simulation, it exhibited an augmented interaction profile, forming two hydrogen bonds and two hydrophobic interactions with His64,Gln67, Leu198, and Pro201 inside the CA VI catalytic site.

Within the confines of the current study, the outcomes from the MTT assay substantiate the cytotoxic attributes of cynarin against the HCT-116 cell line. Notably, the investigation unveiled a correlation between increasing cynarin concentration and inhibition of cancer cell survival. Thus, the idea that cynarin and structurally analogous compounds could serve as therapeutic agents in conjunction with conventional treatment modalities is a plausible hypothesis. Nonetheless, future investigations should comprehensively elucidate the interactions between cynarin and the human serum albumin (HSA) protein. HSA is the primary transport vehicle for an extensive array of molecules in the bloodstream and significantly influences the effectiveness, metabolism, distribution, and clearance of pharmaceutical compounds.37

Angelini et al.38 showed that cynarin notably amplified cytotoxicity and the doxorubicin concentration in doxorubicin-resistant uterine sarcoma cells (MES-SA/Dx5) compared with control cells exposed solely to doxorubicin. In summation, we conclude that kaempferol 3-rutinoside-4-glucoside, orientin, kaempferol 3-rutinoside-7-sophoroside, cynarin, and chlorogenic acid can inhibit CA VI activity at the pM scale. Those compounds emerged as the most robust CA VI inhibitors among the metabolites investigated here. Furthermore, the docked conformations of kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin maintained their stability in 40-ns computer simulations, suggesting the potential suitability of these metabolites for medicinal development targeting obesity, salivary gland carcinoma, and dental caries. However, comprehensive in vitro, in vivo, and clinical trials are needed to validate and explore these results.

Each residue within the enzymatic active site is pivotal in orchestrating intricate biochemical activities, and some of those roles have been definitively characterized. For example, Asn62 and Gln92 participate in binding interactions with specific CA VI activators, notably histamine and L-histidine. Concomitantly, His64 serves as a proton donor and acceptor, mediating vital hydrogen bonding interactions. His94, His96, and His119 collectively contribute to the meticulous maintenance of Zn+2 coordination within the catalytic pocket of CA VI. Furthermore, Thr199 has a critical responsibility in establishing binding interactions with the enzyme substrate.39,40

Significant insights from previous studies underscore the pronounced effects of mutations on specific residues. Notably, mutagenesis at Asn62 markedly attenuates enzyme activity, whereas analogous manipulations of His64 severely impede CO2 hydrase functionality. Similarly, mutagenesis targeting His94 substantially reduces CO2 hydrase and p-nitrophenyl acetate esterase activity, concurrently destabilizing zinc binding. Furthermore, perturbations in His119 led to a profound reduction in CA VI activity.39,40

Therefore, it is conceivable that binding between the identified top-ranked CA VI inhibitors and residues within the active site of the enzyme could precipitate multifaceted mechanisms of enzymatic attenuation, including (1) decreasing the binding affinity of histamine and L-histidine to the CA VI allosteric site, (2) attenuating CO2 hydrase activity, and (3) compromising the stability of Zn+2 coordination.

The authors thank the support of the Dental Research Center, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Study concept and design: EY, AT; acquisition of data: MK, MS, AT; analysis and interpretation of data: EY, MK, ZK, MS, AT; drafting of the manuscript: AT; critical revision of the manuscript: EY, ZK; statistical analysis: MS; administrative, technical, or material support: MS; and study supervision: EY, AT.

Fig. 1. ΔGbinding values between the carbonic anhydrase VI (CA VI) active site and this study’s top-ranked compounds and the positive control inhibitor. The X-axis presents the names of the compounds, and the Y-axis demonstrates their corresponding ΔGbinding values (kcal/mol). The green spot illustrates the positive control inhibitor, and the red, yellow, and cyan diamonds represent flavonoids, anthraquinones, and cinnamic acids, respectively.
Fig. 2. Interactions between residues within the carbonic anhydrase VI (CA VI) catalytic site and the top-ranked flavonoid, anthraquinone, and cinnamic acid derivative in this study: (A) kaempferol 3-rutinoside-4-glucoside, (B) aloe-emodin 8-glucoside, and (C) cynarin. Left and right images present interactions before and after molecular dynamic simulations, respectively. LEU, leucine; HIS, histidine; TRP, tryptophan; THR, threonine; ASN, asparagine; GLN, glutamine; TYR, tyrosine; PRO, proline; VAL, valine; PHE, phenylalanine; GLU, glutamic acid; ARG, arginine; ILE, isoleucine; GLY, glycine.
Fig. 3. (A) Root mean square deviation (RMSD) for backbone atoms of carbonic anhydrase VI (CA VI) complexed with kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin. The X-axis presents the simulation time, and the Y-axis shows the RMSD. (B) Root mean square fluctuation (RMSF) for backbone atoms of CA VI complexed with kaempferol 3-rutinoside-4-glucoside, aloe-emodin 8-glucoside, and cynarin. The secondary structure of CA VI was taken from the UniProt database. Black, pink, and blue represent β-strand, α-helix, and turn structures, respectively. The X-axis presents the name and number of residues, and the Y-axis demonstrates the RMSF. The residues incorporated inside the CA VI active site are marked with an asterisk. Residues marked with red asterisks showed lower fluctuation than residues marked with blue asterisks. HIS, histidine; GLY, glycine; PHE, phenylalanine; GLN, glutamine; LEU, leucine; ASP, aspartic acid; VAL, valine; LYS, lysine; THR, threonine; ALA, alanine; ASN, asparagine; SER, serine; PRO, proline; GLU, glutamic acid; TRP, tryptophan.
Fig. 4. Superimposed structures of carbonic anhydrase VI complexed with (A) kaempferol 3-rutinoside-4-glucoside, (B) aloe-emodin 8-glucoside, and (C) cynarin before and after 40-ns molecular dynamic (MD) simulations. Green and brown represent the protein chain before and after MD simulations, respectively. Blue and red represent small molecules before and after MD simulations, respectively.

Gibbs free energy and Ki values between 46 flavonoids, 21 anthraquinones, 12 cinnamic acid derivatives, a positive control inhibitor, and the CA VI active site

PubChem ID Ligand name ΔGbinding Inhibition constant
A) Flavonoids
44258844 Kaempferol 3-rutinoside-4'-glucoside –15.60 3.69 pM
5281675 Orientin –13.92 62.48 pM
44258853 Kaempferol 3-rutinoside-7-sophoroside –12.70 493.64 pM
5281600 Amentoflavone –12.24 1.07 nM
5280805 Rutin –12.20 1.15 nM
5280804 Isoquercitrin –11.73 2.51 nM
442664 Vicenin-2 –11.37 4.63 nM
5280441 Vitexin –10.95 9.34 nM
5280459 Quercitrin –10.86 10.93 nM
5282102 Astragalin –10.78 12.61 nM
5353915 Quercetin-3-rhamnoside –10.73 13.66 nM
10095180 Kaempferol 7-O-glucoside –10.60 17.00 nM
5318767 Nicotiflorin –10.49 20.56 nM
5280637 Cynaroside –10.46 21.40 nM
72936 Sophoraflavanone G –9.45 118.24 nM
5280704 Apigenin-7-glucoside –9.17 190.51 nM
5316673 Afzelin –9.13 202.70 nM
471 Dihydroquercetin –8.99 255.12 nM
5280544 Herbacetin –8.95 273.65 nM
9911508 Astragarin –8.88 309.23 nM
5281614 Fisetin –8.79 360.43 nM
14309735 Xanthogalenol –8.61 490.73 nM
5317435 Fustin –8.43 662.45 nM
5281672 Myricetin –8.27 861.54 nM
439533 Taxifolin –8.22 942.96 nM
5281670 Morin –8.10 1.15 μM
5281612 Diosmetin –8.02 1.35 μM
5280863 Kaempferol –7.99 1.40 μM
5281654 Isorhamnetin –7.81 1.87 μM
639665 Xanthohumol –7.79 1.95 μM
638278 Isoliquiritigenin –7.37 3.99 μM
5281607 Chrysin –7.33 4.21 μM
629440 Hemileiocarpin –7.28 4.60 μM
72281 hesperetin –7.19 5.39 μM
5280443 Apigenin –7.09 6.40 μM
5280445 Luteolin –7.09 6.30 μM
5318998 Licochalcone A –6.98 7.66 μM
5280681 3-O-methylquercetin –6.87 9.21 μM
5280343 Quercetin –6.79 10.52 μM
443639 Epiafzelechin –6.66 13.09 μM
9064 Catechin –6.47 18.19 μM
25201019 Ponciretin –6.47 18.13 μM
124052 Glabridin –6.43 19.21 μM
1203 Epicatechin –6.38 21.11 μM
10680 Flavone –5.42 107.09 μM
5280378 Formononetin –5.35 118.82 μM
B) Anthraquinones
126456371 Aloe-emodin 8-glucoside –10.84 11.35 nM
3663 Hypericin –10.50 20.09 nM
442731 Pulmatin (chrysophanol-8-0-glucoside) –10.08 41.18 nM
99649 Emodin-8-glucoside –9.80 65.43 nM
10168 Rhein –8.46 629.59 nM
101286218 Rhodoptilometrin –8.37 734.07 nM
10208 Chrysophanol –8.21 957.38 nM
361510 Emodic acid –8.19 995.93 nM
10207 Aloe-emodin –8.11 1.14 μM
6683 Purpurin –8.04 1.29 μM
6293 Alizarin –7.99 1.40 μM
3220 Emodin –7.62 2.61 μM
92826 Sennidin A –7.51 3.14 μM
10459879 Sennidin B –7.49 3.23 μM
2950 Danthron –7.45 3.46 μM
10639 Physcion –7.08 6.42 μM
3083575 Obtusifolin –7.02 7.13 μM
124062 Rubiadin –6.53 16.26 μM
160712 Nordamnacanthal –5.58 101.69 μM
2948 Damnacanthal –5.30 111.69 μM
442753 Knipholone –5.05 199.97 μM
C) Cinnamic acids
6124212 Cynarin –14.93 11.33 pM
1794427 Chlorogenic acid –12.42 783.13 pM
5281792 Rosmarinic acid –11.85 2.06 nM
5281759 Caffeic acid 3-glucoside –9.47 113.89 nM
5281787 Caffeic acid phenethyl ester –8.11 1.14 μM
5372945 N-p-coumaroyltyramine –6.37 21.45 μM
637540 o-Coumaric acid –5.70 66.07 μM
637775 Sinapinic acid –5.24 143.22 μM
445858 Ferulic acid –5.09 184.46 μM
637542 p-Coumaric acid –4.75 332.19 μM
444539 Cinnamic acid –4.52 482.11 μM
689043 Caffeic acid –4.19 853.65 μM
D) Possitive control inhibitor
3295 Ethoxzolamid –6.70 49.54 uM

CA VI, carbonic anhydrase VI.

Interaction modes between the CA VI catalytic site, top-ranked herbal inhibitors in this study, and the CA VI positive control inhibitor

Ligand name Hydrogen bond (distance A) Hydrophobic interaction (distance A) Miscellaneous (distance A)
A) Flavonoids
Kaempferol 3-rutinoside-4'-glucoside (before MD) Thr200 (4.67) Tyr131 (5.03); His64* (5.36); Trp5 (6.23) NA
Kaempferol 3-rutinoside-4'-glucoside (after MD) Asn62* (3.69); Pro201 (4.29); Tyr131 (4.96); Gln92* (4.63); Gln67 (4.81); Glu69 (4.91, 4.92) NA NA
Orientin Gln135 (3.82, 3.36); Pro201 (4.64, 4.41); His64* (4.40); Asn62* (4.64) Pro202 (6.27, 6.41); Leu198 (6.32) NA
Kaempferol 3-rutinoside-7-sophoroside Thr200 (4.10) NA His94* (4.35)
Amentoflavone Pro202 (4.43) Val121 (4.42); Leu198 (5.13, 7.03); Tyr131 (7.18) His64* (5.29) NA
Rutin Gln67 (4.34); Gln135 (4.81, 4.65) His94* (7.39); Pro202 (5.91) NA
Isoquercitrin His64* (4.93) Leu198 (6.86); Trp5 (7.19); Pro202 (5.27) NA
Vicenin-2 Asp72 (4.35); Gln67 (4.75, 4.19, 4.81); Thr200 (3.88) Tyr131 (5.58); Ile91 (5.18) NA
Vitexin Pro201 (4.33, 4.46); Pro202 (4.85); Gln135 (3.41, 3.85) Leu198 (4.49, 7.11); Pro202 (4.86); Val121 (7.10) NA
Astragalin Pro201 (4.26); Thr200 (4.43) Leu198 (5.67, 7.33); Pro202 (5.96, 5.34) NA
Quercetin-3-rhamnoside His64* (3.97); Thr200 (3.69, 3.71); Pro201 (4.78); Gln92* (4.78) Val121 (6.00) NA
Kaempferol 7-O-glucoside Gln135 (4.19); Pro202 (4.96) Val121 (5.04); His64* (4.69); Trp5 (6.21) NA
Nicotiflorin Gln135 (4.02); Glu69 (3.36); His94* (4.39); Thr200 (4.09) Tyr131 (6.55) NA
Cynaroside Pro202 (4.93); Pro201 (4.95); Tyr131 (4.97); Gln92* (4.94) His64* (6.73); TRP209 (6.54) NA
B) Anthraquinones
Aloe-emodin 8-glucoside (before MD) Glu69 (4.70); Thr199* (2.93); Thr200 (3.13); Leu198 (3.71) Val121 (5.32); His94* (6.02) NA
Aloe-emodin 8-glucoside (after MD) Thr200 (3.27, 3.55); Pro201 (4.11, 4.41) His94* (6.94) NA
Hypericin Pro201 (4.55) Leu198 (5.26, 6.80); Pro202 (5.68); Val121 (6.03); Tyr131 (6.66, 7.04) NA
Pulmatin (chrysophanol-8-0-glucoside) Glu69 (4.55); Thr200 (3.01) Val121 (6.03); Leu198 (4.78) Trp209 (7.31); His94* (6.94, 6.05) NA
C) Cinnamic acids
Cynarin (before MD) Pro201 (4.99) Leu198 (6.32) NA
Cynarin (after MD) Pro201 (3.58); Gln67 (4.62) Leu198 (6.48); His64* (5.98) NA
Chlorogenic acid Thr200 (3.78); Pro201 (4.62) Val121 (5.58); Leu198 (5.24) NA
Rosmarinic acid Pro201 (4.65, 4.21); Pro202 (4.12) Val121 (6.86); Leu198 (4.47) NA
D) Positive control inhibitor
Ethoxzolamid His119* (4.56, 4.44); Thr199* (4.63, 3.57) Val121 (5.01, 5.01); Tyr131 (6.50) Trp209 (7.09); His94* (6.31); His96* (7.48, 7.30)

*The pivotal residues within the enzyme’s active site.

CA VI, carbonic anhydrase VI; MD, molecular dynamic; Thr, threonine; Tyr, tyrosine; His, histidine; Trp, tryptophan; NA, not available; Asn, asparagine; Pro, proline; Gln, glutamine; Glu, glutamic acid; Leu, leucine; Val, valine; Asp, aspartic acid; Ile, isoleucine.

  1. Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68.
    Pubmed CrossRef
  2. Supuran CT and De Simone G. Carbonic anhydrases as biocatalysts: from theory to medical and industrial applications. Elsevier; 2015.
  3. Frost SC. Physiological functions of the alpha class of carbonic anhydrases. Subcell Biochem 2014;75:9-30.
    Pubmed CrossRef
  4. Mboge MY, Mahon BP, McKenna R, Frost SC. Carbonic anhydrases: role in pH control and cancer. Metabolites 2018;8:19.
    Pubmed KoreaMed CrossRef
  5. Mincione F, Starnotti M, Masini E, Bacciottini L, Scrivanti C, Casini A, et al. Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma. Bioorg Med Chem Lett 2005;15:3821-7.
    Pubmed CrossRef
  6. Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725-35.
    Pubmed CrossRef
  7. Thiry A, Dogné JM, Supuran CT, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 2007;7:855-64.
    Pubmed CrossRef
  8. Di Fiore A, Supuran CT, Scaloni A, De Simone G. Human carbonic anhydrases and post-translational modifications: a hidden world possibly affecting protein properties and functions. J Enzyme Inhib Med Chem 2020;35:1450-61.
    Pubmed KoreaMed CrossRef
  9. Kivelä J, Parkkila S, Waheed A, Parkkila AK, Sly WS, Rajaniemi H. Secretory carbonic anhydrase isoenzyme (CA VI) in human serum. Clin Chem 1997;43:2318-22.
    Pubmed CrossRef
  10. Murakami H and Sly WS. Purification and characterization of human salivary carbonic anhydrase. J Biol Chem 1987;262:1382-8.
    Pubmed CrossRef
  11. Karhumaa P, Leinonen J, Parkkila S, Kaunisto K, Tapanainen J, Rajaniemi H. The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk. Proc Natl Acad Sci U S A 2001;98:11604-8.
    Pubmed KoreaMed CrossRef
  12. Kaseda M, Ichihara N, Nishita T, Amasaki H, Asari M. Immunohistochemistry of the bovine secretory carbonic anhydrase isozyme (CA-VI) in bovine alimentary canal and major salivary glands. J Vet Med Sci 2006;68:131-5.
    Pubmed CrossRef
  13. Leinonen JS, Saari KA, Seppänen JM, Myllylä HM, Rajaniemi HJ. Immunohistochemical demonstration of carbonic anhydrase isoenzyme VI (CA VI) expression in rat lower airways and lung. J Histochem Cytochem 2004;52:1107-12.
    Pubmed CrossRef
  14. Kazokaitė J, Kairys V, Smirnovienė J, Smirnov A, Manakova E, Tolvanen M, et al. Engineered carbonic anhydrase VI-mimic enzyme switched the structure and affinities of inhibitors. Sci Rep 2019;9:12710.
    Pubmed KoreaMed CrossRef
  15. Pastorek J and Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol 2015;31:52-64.
    Pubmed CrossRef
  16. Picco DC, Lopes LM, Rocha Marques M, Line SR, Parisotto TM, Nobre Dos Santos M. Children with a higher activity of carbonic anhydrase VI in saliva are more likely to develop dental caries. Caries Res 2017;51:394-401.
    Pubmed CrossRef
  17. Picco DC, Marangoni-Lopes L, Parisotto TM, Mattos-Graner R, Nobre-Dos-Santos M. Activity of carbonic anhydrase VI is higher in dental biofilm of children with caries. Int J Mol Sci 2019;20:2673.
    Pubmed KoreaMed CrossRef
  18. Al-Mahdi R, Stangvaltaite-Mouhat L, Aleksejuniene J, Stankeviciene I, Tommeras B, Puriene A, et al. Association between carbonic anhydrase VI gene copy number variations and dental caries experience. Caries Res 2023;57:67-73.
    Pubmed CrossRef
  19. Choi EY, Park CY, Ho SH, Park SJ, Kim D, Han B, et al. Anti-obesity effects of artemisia annua extract in Zucker fatty rats and high-fat diet Sprague Dawley rats through upregulation of uncoupling protein 1. J Obes Metab Syndr 2021;30:32-43.
    Pubmed KoreaMed CrossRef
  20. Hosseini Z, Ghaedi H, Ahmadi M, Hosseini SA. Lipid-lowering effects of concurrent training and green tea consumption in overweight women. J Obes Metab Syndr 2020;29:313-9.
    Pubmed KoreaMed CrossRef
  21. Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariati MA, Khan IA, et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharmacother 2019;112:108612.
    Pubmed CrossRef
  22. Ververidis F, Trantas E, Douglas C, Vollmer G, Kretzschmar G, Panopoulos N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: chemical diversity, impacts on plant biology and human health. Biotechnol J 2007;2:1214-34.
    Pubmed CrossRef
  23. De P, Baltas M, Bedos-Belval F. Cinnamic acid derivatives as anticancer agents: a review. Curr Med Chem 2011;18:1672-703.
    Pubmed CrossRef
  24. Taherkhani A, Moradkhani S, Orangi A, Jalalvand A. In silico study of some natural anthraquinones on matrix metalloproteinase inhibition. Res J Pharmacogn 2021;8:37-51.
  25. Malik EM and Müller CE. Anthraquinones as pharmacological tools and drugs. Med Res Rev 2016;36:705-48.
    Pubmed CrossRef
  26. Folliero V, Dell'Annunziata F, Roscetto E, Amato A, Gasparro R, Zannella C, et al. Rhein: a novel antibacterial compound against Streptococcus mutans infection. Microbiol Res 2022;261:127062.
    Pubmed CrossRef
  27. Molaei P, Savari M, Mahdavinezhad A, Najafi R, Afshar S, Esfandiari N, et al. Highlighting functions of apoptosis and circular RNAs in colorectal cancer. Pathol Res Pract 2023;248:154592.
    Pubmed CrossRef
  28. Masumi M, Noormohammadi F, Kianisaba F, Nouri F, Taheri M, Taherkhani A. Methicillin-resistant Staphylococcus aureus: docking-based virtual screening and molecular dynamics simulations to identify potential penicillin-binding protein 2a inhibitors from natural flavonoids. Int J Microbiol 2022;2022:9130700.
    Pubmed KoreaMed CrossRef
  29. Taherkhani A, Moradkhani S, Orangi A, Jalalvand A, Khamverdi Z. Molecular docking study of flavonoid compounds for possible matrix metalloproteinase-13 inhibition. J Basic Clin Physiol Pharmacol 2020;32:1105-19.
    Pubmed CrossRef
  30. Zuo B, Liao ZX, Xu C, Liu C. Two novel prenylated kaempferol derivatives from fresh bud's fur of Platanus acerifolia and their anti-proliferative activities. Nat Prod Res 2016;30:2523-8.
    Pubmed CrossRef
  31. Nakamura Y, Chang CC, Mori T, Sato K, Ohtsuki K, Upham BL, et al. Augmentation of differentiation and gap junction function by kaempferol in partially differentiated colon cancer cells. Carcinogenesis 2005;26:665-71.
    Pubmed CrossRef
  32. Amjad E, Sokouti B, Asnaashari S. A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound. Cancer Cell Int 2022;22:260.
    Pubmed KoreaMed CrossRef
  33. Patra JK, Kim ES, Oh K, Kim HJ, Kim Y, Baek KH. Antibacterial effect of crude extract and metabolites of Phytolacca americana on pathogens responsible for periodontal inflammatory diseases and dental caries. BMC Complement Altern Med 2014;14:343.
    Pubmed KoreaMed CrossRef
  34. Mohammed AE, Ameen F, Aabed K, Suliman RS, Alghamdi SS, Safhi FA, et al. In-silico predicting as a tool to develop plant-based biomedicines and nanoparticles: Lycium shawii metabolites. Biomed Pharmacother 2022;150:113008.
    Pubmed CrossRef
  35. Kim DB, Unenkhuu B, Kim GJ, Kim SW, Kim HS. Cynarin attenuates LPS-induced endothelial inflammation via upregulation of the negative regulator MKP-3. Anim Cells Syst (Seoul) 2022;26:119-28.
    Pubmed KoreaMed CrossRef
  36. Chen Y, Chen X, Luo G, Zhang X, Lu F, Qiao L, et al. Discovery of potential inhibitors of squalene synthase from traditional Chinese medicine based on virtual screening and in vitro evaluation of lipid-lowering effect. Molecules 2018;23:1040.
    Pubmed KoreaMed CrossRef
  37. Molaei P, Mahaki H, Manoochehri H, Tanzadehpanah H. Binding sites of anticancer drugs on human serum albumin (HSA): a review. Protein Pept Lett 2022;29:651-75.
    Pubmed CrossRef
  38. Angelini A, Di Pietro R, Centurione L, Castellani ML, Conti P, Porreca E, et al. Inhibition of P-glycoprotein-mediated transport by S-adenosylmethionine and cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells. J Biol Regul Homeost Agents 2012;26:495-504.
  39. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019;47(D1):D506-15.
    Pubmed KoreaMed CrossRef
  40. Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2021;49(D1):D10-7.
    Pubmed KoreaMed CrossRef